In our opinion, the use of ADT in a cohort with mostly high-risk prostate cancer patients as evaluated by Afshar-Oromieh et al. is also a surrogate for high tumour burden and high PSA levels. This evidence concerns the gene PROS1 and Familial prostate cancer.